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Abstract 
Mass spectrometry-based proteomics methodology has become an important tool in elucidating some of the 
underlying mechanisms involved in cardiovascular disease. The present review provides details on selected impor-
tant protein targets where highly selective and specific mass spectrometry-based approaches have led to impor-
tant new findings and provided new mechanistic information. The role of six proteins involved in the etiology of 
cardiovascular disease (acetylated platelet cyclooxygenase-1, serum apolipoprotein A1, apolipoprotein C-III, serum 
C-reactive protein, serum high mobility group box-1 protein, insulin-like growth factor I) and their quantification 
has been discussed. There are an increasing number of examples where highly selective mass spectrometry-based 
quantification has provided new important data that could not be obtained with less labor intensive and cheaper 
immunoassay-based procedures. It is anticipated that these findings will lead to significant advances in a number of 
important issues related to the role of specific proteins in cardiovascular disease. The availability of a new generation 
of high-resolution high-sensitivity mass spectrometers will greatly facilitate these studies so that in the future it will be 
possible to analyze serum proteins of relevance to cardiovascular disease with levels of specificity and/or sensitivity 
that cannot be attained by immunoassay-based procedures.
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Introduction to targeted proteomics 
and cardiovascular disease
Proteomics is increasingly providing clues to the under-
lying mechanism of cardiovascular disease [1]. However 
in order to translate these more global findings it is often 
necessary to take a more targeted mass spectrometry 
(MS)-based approach, particularly when dealing with 
patient-derived biofluids [2]. The use of liquid chroma-
tography-multiple reaction monitoring (LC–MRM/MS) 
or LC-high resolution (HR) MS for quantification of 
selected proteins has several key advantages when com-
pared with antibody-based methods. The general work-
flow for targeted proteomics (Fig.  1) starts by adding a 
stable isotope labeled protein internal standard, such as 
a stable isotope labeling by amino acids in cell culture 
(SILAC) standard, to a serum or plasma sample. This 
standard has identical physicochemical properties to 
the endogenous protein and so it corrects for any losses 
that occur during the analytical procedure as well as act-
ing a carrier for low abundance proteins. The serum or 
plasma sample is then mixed with buffer and the sample 
is depleted of highly abundance proteins by a variety of 
techniques such as antibody columns, polyacrylamide 
gel electrophoresis, or immunoprecipitation (Fig.  1). 
Proteins are dissolved in urea or thiourea with ammo-
nium bicarbonate, reduced with dithiothreitol, alkylated 
with iodoacetamide, and digested with a protease such 
as trypsin. The resulting digest is desalted and analyzed 
by reversed-phase LC coupled to a triple quadrupole 
or HR mass spectrometer (Fig.  1). Analyte detection by 
LC–MRM/MS is essentially structurally unambiguous 
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by offering absolute selectivity. Even in instances where 
selectivity may be compromised by a co-eluting analyte, 
with isobaric precursor and product ions, these inter-
ferences can often be identified and the method altered 
to eliminate the problem. The ability to assay multiple 
peptides derived from multiple proteins in a single LC–
MRM/MS analysis permits multiplexing to be readily 
conducted. These factors, coupled with the use of stable 
isotope labeled protein internal standards, offer a level 
of specificity and flexibility that cannot be attained by 
standard immunoassay-based methodology. The present 
review will focus on selected important protein targets 
where a highly selective and specific approach has led to 
important new findings and provided new mechanistic 
information. The quantification of six proteins (Table 1), 
acetylated platelet cyclooxygenase-1 (platelet Ac-COX-1) 
[3], serum apolipoprotein A1 (ApoA-I) [4], serum ApoC-
III [5], serum C-reactive protein (CRP), serum high 
mobility group box-1 (HMGB1) [6], and serum insulin-
like growth factor I (IGF-I) [7, 8], which are involved 
in various aspects of cardiovascular disease will be dis-
cussed in detail below. Ultimately, it could be that these 
quantitative methods will simply serve as gold standards 
for other less specific technologies. Therefore, in the 
future, it is conceivable that less labor intensive and less 
expensive approaches can be developed.
Platelet Ac‑COX‑1
COX-1 is a prostaglandin synthetase that is responsible 
for the production of proinflammatory prostaglandins 
(PGs) from arachidonic acid, a 20 carbon fatty acid, at 
a site of injury. Aspirin, which was first synthesized in 
1893, is a non-selective irreversible COX inhibitor. It is 
one of the world’s most widely used therapeutic agents 
through its effectiveness in reducing pain, fever, and 
inflammation. Acetylation of platelet COX-1 to form Ac-
COX-1 occurs after aspirin treatment in  vivo through 
acetylation of serine-529 in the hydrophobic substrate 
binding channel [9]. This irreversibly inactivates the 
platelet COX-1 enzyme. Aspirin is classified as a non-
steroidal anti-inflammatory drug (NSAID) but it dif-
fers from traditional NSAIDs (tNSAIDs), which inhibit 
platelet COX-1 through reversible non-covalent interac-
tions. These tNSAIDs prevent the binding of aspirin to 
serine-529 by occupying the substrate binding channel 
of platelet COX-1 [9]. In 2010, some 12.8 % of US adults 
(29.4 million) were estimated to be taking tNSAIDs 
regularly and 19.0  % (43.6 million) were estimated to 
be taking aspirin chronically for cardioprevention [10]. 
Consequently, chance alone suggests that approximately 
2.4 % of US adults (5.5 million) were chronically exposed 
to both a NSAID and aspirin in 2010. Therefore, it is nec-
essary to assess the antiplatelet effects of tNSAIDs (due 
to reversible COX-1 inhibition), the inhibition of aspirin 
binding to platelet COX-1 by particular tNSAIDs, and 
the irreversible antiplatelet effects of aspirin (due to irre-
versible COX- inhibition) during co-administration of 
particular tNSAIDs. This is extremely challenging using 
conventional methodology [11] but particularly impor-
tant for assessing the effects of tNSAIDs with variable 
and extended half-lives such as naproxen [12].
In order to address this complex problem, a method 
for the direct quantification of Ac-COX-1 was developed 
using a proteomics approach in combination with stable 
isotope dilution liquid chromatography-multiple reaction 
monitoring (LC–MRM)/MS [13]. This has made it possi-
ble to analyze the ability of structurally distinct tNSAIDs 
to inhibit Ac-COX-1 formation through drug–drug 
interactions in  vivo. Initially, combinations of proteases 
were screened in order to find the best way to efficiently 
excise a peptide containing the acetylated serine-529 
from aspirin-modified COX-1. It was found that a com-
bination of two proteases, Glu-C—a serine protease that 
cleaves at the C-terminal side of aspartic or glutamic acid 
residues and trypsin - a serine proteases that cleaves pri-
marily at the C-terminal side of lysine or arginine, except 
when either is followed by proline, efficiently hydrolyzed 
Fig. 1 Workflow for targeted proteomics
Table 1 Summary of assays used for measurements of pro-
teins biomarkers of cardiovascular disease
Protein LC–MS assay References Immunoassay References
Ac-COX-1 SID LC–MRM/MS [13] None available
ApoA-I SID LC–MRM/MS [4] ELISA [24]
ApoC-III LC–HRMS [5] ELISA [40–43]
hsCRP LC–MRM/MS [62–67] ELISA [54–60]
HMGB1 LC–MRM/MS [79, 82, 88] ELISA [83–87]
IGF-I LC–HRMS [108] ELISA [104–107]
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COX-1 to yield the octapeptide –I524GAPFSLK531, which 
had excellent MS ionization characteristics as both the 
acetylated and non-acetylated forms. The stable isotope 
dilution LC–MRM/MS assay that was developed pro-
vided a highly precise and accurate way to assess the 
amount of platelet Ac-COX-1 that was formed in  vivo 
during the administration of various NSAID combina-
tions [3]. Aspirin was shown to acetylate primarily the 
catalytic monomer (rather than the allosteric monomer) 
within the homodimeric COX-1 complex [14]. The sta-
ble isotope dilution LC–MRM/MS assay revealed that 
maximum acetylation occurred on >50 % of the COX-1 
molecules [3]. Therefore, either a fraction of Ac-COX-1 
monomers was not assembled into homodimers and/or 
both the catalytic and allosteric monomers were acety-
lated in some of the homodimers.
The study by Li et al. [3] simulated the chronic dosing 
pharmacokinetics of ibuprofen, naproxen, and celecoxib 
and compared the expected steady-state plasma con-
centrations with those observed 2  h after single dose. 
Chronic dosing with ibuprofen and naproxen in the dose 
range used in the PRECISION trial (Prospective Rand-
omized Evaluation of Celecoxib Integrated Safety Versus 
Ibuprofen or Naproxen) and the Standard Care Versus 
Celecoxib Outcome Trial would result in plasma concen-
trations that are similar to or higher than the concentra-
tions that were found to prevent COX-1 acetylation. This 
means that it is likely that platelet inhibition by aspirin 
will be blocked in patients on these dosing regimens, 
irrespective of the order in which aspirin and the NSAID 
are taken. The levels simulated with celecoxib are in the 
range of the plasma concentrations that were observed to 
have little or no effect on aspirin acetylation.
Fasted healthy volunteers received a single dose of 
aspirin (325 mg) to assess their aspirin-responsiveness. 
In the second study period, after a washout period of at 
least 2 weeks, subjects received a single dose of 600 mg 
ibuprofen, 500  mg naproxen or 200  mg celecoxib in a 
sequential treatment group with an open-label design. 
Two hours after the NSAID, a single dose of aspirin 
(325 mg) was administered. Platelet Ac-COX-1, arachi-
donic acid-induced platelet aggregation, platelet TxB2, 
and urinary 11-dehydro TxB2 were also measured 
before NSAID administration, before aspirin adminis-
tration, and 24  h thereafter. As noted above, the octa-
peptide (I524GAPFSLK531) containing the acetylation 
site, serine-529, from COX-1 was used for quantifica-
tion. Proteins isolated from washed platelets were sep-
arated on a gel and proteolyzed in the presence of the 
stable isotope-labeled internal standards. Assay preci-
sion and accuracy was excellent with limits of detec-
tion and quantification being 200 amol and 3 fmol, 
respectively.
The LC–MRM/MS assay revealed that there were 
potent drug–drug interactions between ibuprofen and 
aspirin and between naproxen and aspirin [3]. Further-
more, a reduction of platelet Ac-COX-1 by just slightly 
more than 10 % resulted in the loss of aspirin-mediated 
inhibition of platelet function. This latter finding is con-
sistent with the large functional COX-1 reserve available 
in platelets [15]. Overall, these findings illustrate how 
difficult it will be to make head-to-head comparisons of 
structurally distinct NSAIDs in clinical studies designed 
to assess their cardiovascular risk when aspirin consump-
tion has not been addressed.
ApoA‑I
ApoA-I is the major protein constituent of high density 
lipoprotein (HDL) particles, accounting for approxi-
mately 65 % of the protein mass [16]. It is a 45.4 kDa pro-
tein that is composed of 396 amino acids. Its biosynthesis 
occurs primarily in the liver and small intestine as a pre-
pro-protein. This protein is cleaved and secreted from the 
liver and intestine as pro-ApoA-I into the blood circula-
tion or the lymphatic system. After cleavage of the pro-
section, the resulting mature ApoA-I is converted into 
lipid-poor ApoA-I particles that absorb free cholesterol. 
A number of metabolic steps then take place including 
the action of lecithin-cholesterol acyltransferase (LCAT) 
in the particles, which rapidly esterifies cholesterol into 
cholesteryl esters (CEs) to generated larger HDL par-
ticles. In addition, cholesteryl ester transfer protein 
(CETP) facilitates the exchange of CE for triacylglycerols 
(TAGs) between ApoB-containing lipoproteins and HDL 
particles. After a series of complex metabolic steps [16], 
the mature HDL particles bind to scavenger receptor 
class B type 1 (SR-B1) or to holo-HDL receptors on the 
liver where TAGs and cholesterol esters are selectively 
absorbed into the liver [17]. This removes cholesterol 
from cells and the circulation to the liver, a process that 
is known as reverse cholesterol transport [18]. The ability 
of HDL to shuttle cholesterol and TAGs from the circula-
tion into the liver provides the most likely explanation for 
the inverse relationship between serum HDL concentra-
tions and risk for coronary heart disease (CHD) risk [19, 
20]. It has been estimated that a 1  % increase in serum 
HDL is associated with a 2  % reduction in the risk to 
develop CHD [21].
The critical role of endogenous ApoA-I biosynthesis in 
the assembly of HDL particles has stimulated numerous 
pharmacological approaches to elevating serum ApoA-
I levels [17]. Statins, which are HMG-CoA reductase 
inhibitors, have proved to be the most successful class of 
drug for increasing HDL levels and lowering CHD risk 
[22]. This reduction in risk occurs through increasing 
HDL concentrations as well as by lowering low density 
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lipoprotein (LDL) concentrations [17]. The lower LDL 
concentrations occur through inhibition of HMG-CoA 
reductase and inhibition of cholesterol biosynthesis [23]. 
HDL concentrations are thought to be increased through 
a reduction of geranylgeranyl pyrophosphate biosynthe-
sis, which in turn prevents geranylgeranylation of RhoA 
leading to an increase in PPARα—a transcription factor 
for ApoA-I [23].
Although, there is clear evidence that up-regulation of 
PPARα by statins results in increased ApoA-I, there is a 
curious discrepancy on the reported efficacy of differ-
ent statins [24]. In a retrospective analysis of data from 
37 trials involving 32,258 patients, there was no increase 
in HDL levels from increasing doses of Zocor (simvas-
tatin, Fig.  2a) and Lipitor (atorvastatin, Fig.  2b) and no 
increase in ApoA-I levels for Zocor (Fig.  2a). Paradoxi-
cally, Apo-A-I levels were reported to actually decline 
with increasing doses of Lipitor even though HDL lev-
els remained constant (Fig.  2b). The most potent of the 
statins (Crestor, rosuvastatin) actually caused a modest 
increase in HDL levels with increasing concentrations of 
the drug but there was no concomitant increase in serum 
ApoA-I concentrations (Fig.  2c). The lack of correlation 
between HDL concentrations and serum ApoA-I sug-
gests that perhaps there could be a problem of specificity 
with the enzyme-linked immunosorbent assay (ELISA) 
used to analyze serum ApoA-I. It is conceivable that 
the three statins could have differential off-target anti-
inflammatory effects at higher doses. However, it is dif-
ficult to reconcile such potential off-target effects with 
decreased serum ApoA-I levels such as those observed 
with Lipitor (Fig. 2b).
In keeping with the possible lack of specificity for 
serum ApoA-I, no ELISA-based studies have detected 
decreased serum ApoA-I levels in samples obtained 
from cigarette smokers in spite of their reduced HDL 
levels when compared with non-smokers [25, 26] and 
their approximately 30 % increase in risk for CHD [27]. 
Our group addressed this potential problem recently. 
Using a conventional ELISA, we were unable to detect 
any differences in serum ApoA-I levels between smok-
ers and non-smokers (Fig.  3b) [4]. However, a more 
specific stable isotope dilution LC–MRM/MS assay 
revealed that there was in fact an almost 20 % decrease 
in serum ApoA-I levels in smokers when compared 
with nonsmokers (Fig.  3b) [4]. This finding is consist-
ent with a significantly increased risk for CHD among 
smokers [27]. In light of our data, previous stud-
ies on ApoA-I levels that were determined by ELISA 
methodology such as the studies on statins discussed 
above [24] will have to be re-evaluated using more 
specific stable isotope dilution LC–MRM/MS-based 
methodology.
Quantitative immunoassays such as ELISAs are widely 
used for quantifying protein biomarkers due to their high-
throughput capabilities and high sensitivity [28]. Immuno-
assays are based on epitope recognition and can suffer from 
technical problems including weak antibody affinity, high 
cross-reactivity and lack of concordance among platforms 
Fig. 2 Percent change from baseline in serum HDL and ApoA-I in 
32,258 patients from 37 randomized studies. Patients were treated 
with different doses of statins. a Zocor (simvastatin). b Lipitor (atorv-
astatin). c Crestor (rosuvastatin). Redrawn with permission from [24]. 
NS not significant
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[29]. Stable isotope dilution LC-selected reaction monitor-
ing (SRM)/MS or LC–MRM/MS can provide a solution 
to these potential problems [4]. Quantification of ApoA-I 
by LC–SRM/MS or LC–MRM/MS employing Absolute 
Quantification (AQUA) peptides has been reported for 
purified ApoA-I, in serum and plasma [4]. Although AQUA 
peptides were added before the tryptic digestion, formation 
and decomposition of individual monitored peptides was 
highly variable. This variability suggests that the selection of 
rapidly formed peptides with no or minor missed cleavages 
and the use of short trypsin incubation times were likely to 
reduce the accuracy. AQUA approach is recommended for 
use with proteins that readily undergo digestion to peptides 
that are stable to further hydrolysis.
Stable isotope labeling by amino acids in cell culture 
(SILAC)-based strategies can provide the most accu-
rate and precise methods for absolute protein quanti-
fication. The use of SILAC-labeled internal standards 
minimizes differences in sample processing and proteo-
lytic digestion between the standard and its endogenous 
counterpart. We developed a method using a spike-in 
SILAC approach to quantify ApoA-I in human serum 
[4]. The SILAC-labeled ApoA-I internal standard used 
was labeled with [13C615N2]-lysine and [13C915N1]-tyros-
ine and expressed in the human kidney HEK293 cell 
line. The recombinant labeled ApoA-I was expressed 
without a tag. SILAC-labeled ApoA-I was spiked into 
serum samples at the beginning of the sample prepara-
tion procedure—before electrophoresis separation and 
tryptic digestion. We compared the measured ApoA1 in 
50 smokers and 50 nonsmokers together with the ones 
from a commercial ELISA kit.
Initial experiments were conducted with five of the 
labeled AQUA peptides but the ratios of light to heavy 
peptides exhibited a wide range, which differed by seven-
fold among peptides even though samples were spiked 
with identical amounts of internal standard. Further, 
large variations were observed for each peptide determi-
nation (3–22  %). Therefore, the accuracy and precision 
of quantification of ApoA-I were highly dependent on 
which particular peptides were chosen. A similar prob-
lem was addressed by the Hoofnagle group [29, 30]. They 
showed that the coefficients of variation (CVs) of meas-
urements that included the digestion step were more 
than two-fold higher than the CVs of measurements per-
formed with predigested samples. Additional causes of 
this inaccuracy may include differences in the behavior of 
the peptides versus protein from sample extraction step 
to protein digestion step.
Initially 15 potentially useful tryptic peptides were 
selected for potential use in the quantitative analysis of 
ApoA-I according to the ranking in the Peptide Atlas. 
These were reduced to nine peptides, which included 
all eight of the tyrosine-containing tryptic peptides and 
spanned amino acids D13 to K238 of the 243 amino acid 
protein. LC–MRM/MS analysis was conducted using 
three transitions for each of the peptides and their corre-
sponding stable isotope peptide standard peptides (Fig. 4).
Fig. 3 Serum ApoA-I levels in control non-smokers and tobacco smokers. a Analysis by ELISA. b Analysis by stable isotope dilution LC–MRM/MS 
using a SILAC labeled Apo-A-I internal standard. Re-drawn with permission from [4]
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Fig. 4 Typical LC–MRM/MS chromatograms of three ion transitions for nine signature ApoA-I peptides (upper) and their stable isotopically labeled 
(heavy) analogs (lower). Reprinted with permission from [4]
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The mean concentrations (±standard deviation) of 
ApoA-I in nonsmokers and smokers were 169.4 (±55.1) 
and 138.2  mg/dl (±48.9), respectively (Fig.  3b). The 
smokers had statistically significant lower serum ApoA-
I concentrations compared with nonsmokers (p  <  0.01). 
All nine serum ApoA-I tryptic peptides also showed the 
same trends in both groups, with a statistically significant 
reduction in eight of the peptides in smokers compared 
with nonsmokers. Peptides VQPYLDDFQK and VSKL-
SALEEYTK showed good correlation in both nonsmok-
ers (r2 = 0.98) and smokers (r2 = 0.90). That confirmed 
that the spike in SILAC-labeled ApoA-I internal stand-
ard procedure corrected for variability in peptide form-
ing during the hydrolysis procedure. Tyrosine-192 has 
been reported as the predominant site of both nitration 
and chlorination by myeloperoxidase in  vivo and was 
also the major site of nitration by peroxynitrite (ONOO-) 
in  vitro. In this study, the correlation of peptide LAEY-
192HAK (r2 = 0.88) was good in nonsmokers, while poor 
(r2 = 0.64) in smokers. These data also provide additional 
confirmation that evaluation of trypsin digestion effi-
ciency before choosing final peptides for quantification as 
suggested previously by Miller et al. can further improve 
the precision and accuracy of protein quantification.
Quantification using SILAC labeled proteins has been 
used in numerous proteomics studies. Rigorous method 
validation using a full-length stable isotope labeled pro-
tein internal standard has been used rarely. The meth-
odology can be employed to explore subtle changes in 
ApoA-I levels as a potential biomarker of cardiovascular 
disease and as a biological response indicator for tobacco 
smoking to complement the use of urinary nicotine 
metabolites. It is noteworthy that the AQUA internal 
standards did not provide adequate accuracy and speci-
ficity for the analysis of serum ApoA. The stable isotope 
dilution LC–MS assay for serum ApoA-I is complex and 
can only be performed in a limited number of laborato-
ries. Unlike widely used simpler and less specific assays 
such as ELISAs, it provides an accurate and highly repro-
ducible assessment of serum ApoA-I concentrations. 
Reduced levels of serum ApoA-I are associated with an 
increased risk for CHD (such as for smokers) and so this 
assay has significant clinical potential in identifying indi-
viduals at risk. The assay will also have clinical utility for 
providing definitive information on the effects of smok-
ing cessation as well as therapeutic interventions in other 
high risk populations with HMG-CoA-reductase inhibi-
tors such as rosuvastatin and atorvastatin and fibrates 
such as fenofibrate or dietary interventions with satu-
rated and cis-monounsaturated fatty acids. Such indi-
vidualization of therapy is currently not possible with the 
assay methodology that is available for analyzing serum 
ApoA-I concentrations in most clinical laboratories.
ApoC‑III
ApoC-III is an 8.8  kDa protein consisting of 79 amino 
acids and so is much smaller than ApoA-I [31]. It is syn-
thesized in the liver but unlike ApoA-I once secreted it 
resides on the surface of LDL and very low density lipo-
protein (VLDL) as well as HDL [32]. Clinical studies have 
revealed that increased serum ApoC-III is a potential 
cardiovascular disease risk factor [33, 34]. The role of 
ApoC-III in cardiovascular disease is related to its abil-
ity to impair plasma lipoprotein metabolism, which 
leads to increased TAG levels [32]. In addition, ApoC-III 
has direct atherogenic properties through its ability to 
stimulate the adhesion of monocytes to endothelial cells 
and induce the production of inflammatory mediators 
[35, 36]. This result is consistent with the finding that a 
genetic defect in the production of ApoC-III is associated 
with reduced TAGs and reduced atherosclerosis [37]. A 
systematic review of 5 retrospective and 7 prospective 
studies provided consistent evidence for an association of 
cardiovascular events with elevated blood ApoC-III lev-
els in plasma or in VLDL and LDL [32]. However, it was 
concluded that more data would be required in order to 
determine the importance of levels of ApoC-III in spe-
cific lipoproteins for cardiovascular risk assessment and 
management [32]. Several hypolipidemic agents includ-
ing fibrates and statins have been reported to decrease 
ApoC-III levels [24]. Furthermore, there is a clear asso-
ciation between elevated TAGs and ischemic vascular 
disease and ischemic heart disease [38]. Consequently, 
ApoC-III, which is involved in the elevation of serum 
TAGs, has become a significant therapeutic target [38, 
39]. In order to determine the efficacy of new therapeutic 
agents it will be important to use the most specific and 
sensitive assay methodology possible.
Most studies of ApoC-III levels in serum, VLDL, and 
LDL that have been conducted to date employed immu-
noassay-based methodology [40–43]. However, the rela-
tively small size of ApoC-III and its high abundance in 
plasma makes it amenable to more specific MS-based 
methodology. A landmark study conducted by Jian et al. 
[5] used a “top down” approach coupled with stable 
isotope labeled protein standards. The method, which 
employed LC-high-resolution time-of-flight (HR-TOF)/
MS made it possible to quantify different glycoisoforms 
of intact ApoC-II in human plasma.
Glycosylation enhances the structural stability or func-
tion of ApoC-III [34]. Plasma ApoC-III is found primarily 
in the unmodified form together with two different gly-
coisoforms [44, 45]. O-linked glycosylation, which occurs 
on a threonine-74, consists of galactose, N-acetyl-galac-
tosamine, together with one or two N-acetylneuraminic 
acid (NeuNAc or sialic acid) residues [5]. In order to 
address this issue a relative quantitation method for 
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glycoisoforms of intact ApoC-III in human plasma using 
LC–HRMS was developed by Jian et al. [5] and compared 
with an LC–MRM/MS method (Fig.  5). A fast solid-
phase extraction procedure was utilized to clean up the 
plasma samples, which were then subjected to LC–HR 
full scan MS analysis. The three most abundant isotopic 
peaks at charge state 5 and 6 were extracted using a nar-
row window (50 mDa). The peak area ratio of different 
glycoisoforms was then calculated and used in an assay 
evaluation and a biomarker study. It was demonstrated 
that reproducibility of the peak area ratio was excel-
lent in plasma obtained from multiple subjects and over 
extended times and various storage conditions.
The LC–HRMS method was applied in a preliminary 
biomarker research study for sample analysis of plasma 
obtained from normal, prediabetic, and diabetic subjects. 
The results showed that there was significant difference 
in the ratios of ApoC-III-1/ApoC-III-0 and ApoC-III-2/
ApoC-III-0 among the different groups. Data from com-
plete full scan HRMS experiments can also be mined 
for other PTMs and proteins. Utilization of an internal 
standard also afforded the possibility of evaluating the 
association of absolute abundance of the glycoisoforms 
to other diseases. The workflow can be easily extended 
to other glycoprotein biomarkers of similar sizes. For 
glycoproteins of larger sizes, immunoaffinity enrichment 
of the targeted protein and proteolytic digestion may be 
needed. The relative quantitation approach in these cases 
is expected to be valid for biomarker research of certain 
diseases. During the study, the chromatographic spectra 
showed that glycosylated ApoC-III-0, ApoC-III-1 and 
ApoC-III-2, were the more abundant species, and they 
were present at charge states of 5, 6, 7, 8, and 9. ApoC-
III-0 gave a much weaker signal, and it could only be 
observed at charge states 5 and 6. The calculated differ-
ence between the observed and theoretical values was 
less than 10  ppm for all ions, indicating excellent MS 
accuracy. Near-baseline separation of the isotopic peaks 
was achieved.
Peak integration for the study was conducted on the 
three most abundant ions, 1570.9104, 1571.0773, and 
1571.2444 (theoretical values), using an extraction win-
dow of 50 mDa. The noise between the isotope peaks 
was excluded, eliminating potential interference. The 
three most abundant isotopic peaks at charge state 5, 
1884.8924, 1885.0927, and 1885.2933 (theoretical values), 
were also extracted. The same procedure was performed 
for ApoC-III-1 and ApoC-III-2. Next, the ratio of ApoC-
III-1 chromatographic peak area to that of ApoC-III-0 
and the ratio of ApoC-III-2 peak area to that of ApoC-
III-0 were calculated and further used in assay evaluation 
and sample analysis. An internal standard was used to 
asses general quality of the assay. A stable isotope labeled 
ApoC-III-0, was synthesized by replacing Ala76, Ala78, 
and Ala79 with [2H4]-Ala and was spiked at the beginning 
of the sample preparation procedure. Horse plasma was 
Fig. 5 Comparison of chromatography obtained from LC–HR/MS analysis (left panel) and LC–MRM/MS analysis (right panel) of ApoC-III (ApoC-III-0) 
and its glycoforms (ApoC-III-1, ApoC-III-2) in human plasma. Reprinted with permission from [5]
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used as a surrogate matrix. In preliminary experiments, 
the horse plasma did not contain interference compo-
nents to human ApoC-III. The peak areas of ApoC-III-0, 
ApoC-III-1, and ApoC-III-2 were directly used in peak 
area ratio calculations. The internal standard was used for 
evaluation of absolute abundance. The ratio of each spe-
cies to the internal standard observed in each sample can 
be calculated to compare the absolute abundance of that 
glycoisoform in different subjects. This technique may be 
suitable for other protein biomarkers where the absolute 
rather than the relative abundance is more relevant to 
the pathological or pharmacological effects to be investi-
gated. The method evaluation was conducted to elucidate 
the capability of the assay to reproducibly obtain the ratio 
values upon repeated analysis (intraday and interday), as 
well as after exposure of the samples to room tempera-
ture, freeze–thaw cycles, and long-term storage.
The full scan LC–HRMS-based “top-down” approach 
affords several major advantages in comparison to “bot-
tom-up”, as well as MRM-based “top-down” approaches. 
In the “bottom-up” approach, selected peptides gen-
erated from enzymatic digestion are monitored as 
surrogates of the protein. In comparison, the HRMS “top-
down” work flow allows acquisition of information from 
the whole protein, as well as multiple PTM species in a 
single run. In addition, full scan HRMS is more efficient 
than the MRM-based. There is no prerequisite to know 
the expected parent ion and product ion, and a generic 
MS method can be used. This HRM approach can also 
provide better specificity than an MRM-based approach. 
Not having to find a good fragment ion was particularly 
useful for ApoC proteins as it was found that there were 
no suitable product ions that could be generated in col-
lision-induced dissociation. As a result, “pseudo-MRM”, 
i.e., monitoring of parent ion to parent ion with very low 
collision energy, had to be conducted, which significantly 
sacrificed the specificity of the assay. In comparison, the 
specificity of HRMS was independent of fragmentation.
Newer HR instruments can provide enough resolution 
to separate the isotope peaks of the targeted glycoisoform 
from the noise, as well as give high mass accuracy. Mul-
tiple isotope peaks at each charge state can be extracted 
using a very narrow window to avoid interference. Usu-
ally, the interference peaks are at a much lower relative 
level in LC–HRMS than in LC–MRM analysis, especially 
for ApoC-III-0, which was present at the lowest abun-
dance among all three species. Nontargeted approaches 
are always desired in order to conduct post acquisition 
data mining to reveal other components, such as bio-
transformation products, different PTM species, or even 
other proteins. The data set could also be screened for 
the truncated form of ApoC-III, which has been associ-
ated with elevated carboxypeptidase due to pancreatic 
disease. If the association of ApoC-III with other diseases 
is found, then the data set can offer retrospective infor-
mation. Mining the patient data can be conducted on an 
as-needed basis to reveal important information relevant 
to the disease status or treatment outcome, as well as to 
identify other potential biomarkers.
High sensitivity (HS) CRP
CRP was originally discovered in serum as an acute phase 
response in pneumonia infection [46]. It was subse-
quently shown to be one of some forty plasma proteins 
that are increased after an inflammatory stimulus [47]. 
CRP is produced mainly by hepatocytes primarily in 
response to cytokine interleukin (IL) 6, an activity that is 
enhanced by IL-1β [48]. CRP is a 45.1 kDa member of the 
small pentraxins family of proteins comprising 224 amino 
acids, which exist in an annular pentameric discoid shape 
[47]. It is an inflammatory mediator that has been widely 
accepted as an important risk indicator that can indepen-
dently predict future cardiovascular events and mortality 
[49–51]. For example, in a meta-analysis of hsCRP levels 
involving 160,000 subjects each standard deviation in log 
normalized hsCRP was associated with an increased risk 
of 1.37 for CHD [52]. Although, there are a number of 
confusing issues that limit the definitive use of hsCRP as 
a biomarker of cardiovascular disease [53], some useful 
guidelines have been developed to address the relation-
ship between hsCRP levels and cardiovascular disease 
risk (Fig. 6) [51].
Assays for hsCRP are typically conducted using ELISA 
methodology with a purified protein standard, a mono-
clonal anti-CRP antibody, and a diluted plasma or serum 
sample [54–60]. There are numerous suppliers of ELISA 
kits that can quantify serum or plasma CRP levels down 
to 1  µg/L. Surprisingly, there have been very few studies 
to compare ELISA with MS-based methods or to exam-
ine whether any post-translational modifications (PTMs) 
to CRP such as acetylation are associated with cardio-
vascular disease. There is one study, which described the 
use of immuno-matrix-assisted laser desorption/ioniza-
tion (MALDI)/MS for the analysis of serum CRP [61]. No 
PTMs on CRP were detected by MALDI/MS [61]. None 
of the four reported LC–MS methods are ideal for protein 
quantification [62–65]. Three of them rely on the addi-
tion of stable isotope labeled peptide internal standards to 
the protein digestion [62–64]. This allows tracking of any 
losses during the subsequent LC–MS procedure but does 
not correct for differences in rates of protein digestion or 
for differential degradation of the labeled peptides during 
hydrolysis [4]. It is noteworthy that there were significant 
differences in the plasma CRP levels between the LC–MS 
assay and established ELISA reported in one of the LC–
MS studies [64]. Unusually, the ELISA method provided 
Page 10 of 18Mesaros and Blair  Clin Proteom  (2016) 13:20 
significantly lower levels for plasma CRP than the LC–MS 
method. One study used a standard addition approach 
using unlabeled CRP protein [65], which does not have 
the rigor that would have been possible if stable isotope 
labeled CRP protein had been available at the time of the 
original study [66]. Therefore, there is a real need for a 
gold standard method in which stable isotope labeled CRP 
is used as the internal standard [66] to ensure that there 
are no confounding variables (such as differential degrada-
tion of the peptide standards) during the hydrolysis step of 
the LC–MS procedure. The availability of this assay could 
potentially provide data to establish improved specificity 
for hsCRP as a biomarker of cardiovascular disease.
Williams and Muddiman used a protein cleavage (pro-
teolysis) coupled with isotope dilution (PC-ID) MS meth-
odology for the standardized measurements of CRP. 
The ideal PC-IDMS requires complete protein cleavage, 
which produces a 1:1 molar ratio between the initial 
intact protein and the peptide or peptides to be analyzed. 
The quantification using IDMS is based on the ratio of 
the response of the labeled internal standard peptide to 
that of the unlabeled peptide resulting from the digestion 
of the particular protein of interest. The ability to quan-
tify proteins with PTMs has been demonstrated by hav-
ing PTMs incorporated onto synthetic internal standard 
peptides. CRP was quantified in human plasma with-
out the use of immunoaffinity chromatography or other 
separation techniques using PC-IDMS. The method used 
nanoflow LC and a triple quadrupole mass spectrom-
eter operating in SRM/MS mode. The results from the 
LC–SRM/MS assay were compared with the results from 
an immunoassay test. The method was used to measure 
CRP levels in ovarian cancer patients but can be easily 
used in cardiovascular patients. The reduction in sample 
processing minimizes the loss of the analyte of interest 
and minimizes the variance in analytical results caused 
by the implementation of immunoaffinity and size exclu-
sion separations. The addition of the internal standard to 
Fig. 6 The relationship of inflammation to cardiovascular risk is linear across a wide range of hsCRP values. Blue bars represent crude relative risks; 
red bars represent relative risks adjusted for traditional Framingham risk factors. Reprinted with permission from [51]
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plasma at the beginning of the process accounted for any 
losses in processing.
Four peptides were synthesized and utilized as possible 
internal standards based on a tryptic digestion of purified 
CRP analyzed on a hybrid LTQ-Fourier transform-ion 
cyclotron resonance mass spectrometer. The synthesized 
peptides were then dissolved and examined for purity 
and one naturally occurring peptide ESDTSYVSLK 
(tpCRP14–23 tryptic peptide from CRP, amino acids 
14–23) was used as a standard. The concentrations of 
both the tpCRP14–23 and the isotopically labeled form 
used as an internal standard were verified by the Scopes 
method, which allowed for quantification of the stock 
solutions. The transitions used for the naturally occur-
ring form and the internal standard minimized the inter-
ferences from other possible tryptic peptides that occur 
from tryptic digestion of human plasma. The method was 
evaluated for robustness after running more than 100 
plasma samples and was found to be very reliable even 
if a new column needed to be used for the last set of the 
samples. The use of the internal standard peptide and the 
specificity of SRM/MS afforded the quantification of the 
tpCRP14–23 in the presence of other components from 
the plasma samples.
All samples analyzed by the PC-IDMS method were 
sent to an independent laboratory to have an ELISA anal-
ysis performed for validation. ELISA utilized a polyclonal 
antibody and was designated as a wide range/high sensi-
tivity CPR test. The linear regression for the comparison 
of the values obtained by LC–MRM/MS and ELISA had 
R2 = 0.9708 which indicated a good correlation between 
CRP concentrations determined utilizing the PC-IDMS 
method and the ELISA wide-range hsCRP test. However, 
the concentrations obtained by PC-IDMS were much 
higher. This disparity in the values reported from differ-
ent detection methods means that a reference range must 
be determined for each method, such that the values 
attained can provide appropriate information.
Several years later, Kilpatrick et  al. [66] expressed 
15N-labeled CRP in Escherichia coli and Pichia pastoris 
to be used as an internal standard in MS-based assays. 
Bacterial heterologous protein expression has the ben-
efit of producing large quantities of protein but often has 
severe limitations regarding protein solubility, folding 
structure and PTMs-particularly disulfide bonds, which 
are often crucial to correct protein folding. Yeast expres-
sion systems offer the closest environment resembling 
the human cell for the nascent protein, including homol-
ogous chaperone proteins, non-reducing cytoplasm 
and secretion mechanisms but usually in lower yields. 
15N-labeled rCRP (15N-rCRP) was generated in both bac-
terial and eukaryotic expression systems for use as the 
internal standard in LC–MS [66].
The vector pCRPWT5 was sequenced to verify the 
encoding of the CRP protein (amino acids 19–224) with-
out its native secretory signal sequence. The vector was 
transformed into the E. coli bacterial strain and rCRP 
protein expression was induced for 24  h using 15NH4Cl 
as the sole nitrogen source in the culture medium. Final 
purification was performed with a p-aminophenylphos-
phorylcholine column utilizing the binding affinity of 
the pentameric form of CRP for phosphorylcholine. The 
production of 15N-rCRP was extremely inefficient and 
the yield was too low to be practical. They also expressed 
rCRP in P. pastoris for the generation of 15N-labeled 
protein. Eukaryotic systems benefit the heterologous 
expression of CRP by avoiding aggregation and protein 
mis-folding associated with bacterial systems, presum-
ably due to the conservative nature of the chaperone 
proteins and similarities in cytoplasmic and organelle 
composition. Protein expression was induced by metha-
nol addition in minimal medium containing (15NH4)2SO4 
as the sole nitrogen source leading to the secretion of 
15N-labeled rCRP into the culture medium. The cells were 
removed from the medium, which was directly applied to 
a p-aminophenylphosphorylcholine column and purified 
in a one-step process. The yield was about 50-fold greater 
than with E. coli. Mass determination of newly purified 
protein was performed by MALDI–MS that indicated 
a main peak at m/z 23,705 instead of the expected m/z 
23,307 for 15N-rCRP. The mass difference was consistent 
with the mass of the sequence, EAEA, which is known 
to be incompletely processed from some proteins in 
this expression system. MALDI MS/MS analysis of the 
sequence of this peptide also confirmed the addition of 
the EAEA sequence on the amino terminus.
The average [15N]-incorporation percentage was 
98.2 %, making this approach useful for generating inter-
nal standard for LC–MS. The ability of the 15N-rCRP to 
produce linear responses within the mass spectrometer 
was assessed by digesting a series of samples of puri-
fied human CRP (ranging from 0.3 to 2 μg) each spiked 
with 1 μg of 15N-rCRP. The ratios of the protein quanti-
ties, as well as their response ratios, is a true reflection 
of the intended use of the labeled protein as an internal 
standard for which it must have a linear relationship to 
native CRP in the trypsin proteolysis and subsequent 
mass spectrometry. The ratio of the mass of the unla-
beled to labeled CRP was compared to the ratio of the 
peak response areas for each corresponding protein. 
There was a linear relationship of the ratios (r2  >  0.99). 
The slope of the regression line would be expected to 
be equal to 1 in order to truly indicate that full digestion 
equivalency was achieved for the 15N-rCRP. The slope 
was slightly less than 1 probably due to the uncertainty 
associated with the stock concentrations of protein. The 
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difference shouldn’t impact the use of 15N-rCRP as an 
internal standard because of the strong linear relation-
ship, which exists to the native CRP. A common applica-
tion of a labeled internal standard in ID–MS is to use as 
a constant volume spike. As long as the concentration of 
the spiked material is of appropriate scale to the expected 
value, the analysis will be normalized to the volume of the 
spiked material and the actual concentration of the spike 
is not required for concentration assignment as long as 
the protein concentration of the standard CRP used for 
the calibration curve is accurate.
LC–MS/MS analysis of increasing quantities of puri-
fied human CRP with constant quantity of P. pasto-
ris expressed 15N-rCRP was done after digestion with 
trypsin. A total of 12 transitions from 5 peptides were 
monitored for both the labeled and natural forms. The 
response ratio was calculated by dividing the response 
area for the natural form by the corresponding response 
area of the labeled form. The response ratio of all the pep-
tides were averaged at each amount and plotted against 
the corresponding mass ratio of natural-to-labeled CRP. 
Use of the expressed 15N-rCRP as an ID–MS internal 
standard provides the capability to normalize an analysis 
for a number of aspects such as recovery, digestion, vol-
ume transfers, MS ionization and instrument response 
drift. Accounting for these variables reduces measure-
ment uncertainties in development of the quantification 
methods required for the generation of needed reference 
materials in the standardization of this important clinical 
analyte.
In the report by Kuhn et al. [62], synthetic peptides of 
CRP containing a uniformly labeled [13C]-leucine were 
added to tryptic digests of human serum and analyzed 
on a triple quadrupole mass spectrometer by MRM/MS. 
This provided selective, sensitive, and reproducible detec-
tion of both the labeled peptide and the corresponding 
endogenous CRP peptide. Quantification of CRP levels 
in patient serum was determined by measuring the ratio 
of the endogenous tryptic peptide of CRP against the 
[13C]-labeled synthetic peptide standard. For each patient 
sample analyzed by the method, the values obtained by 
MS were compared to the results of an immunoassay that 
is specific for CRP. Synthetic peptides representing the 
sequences of four trypsin cleavage products of CRP were 
used: ESDTSYVSLK, QDNEILIFWSK, APLTKPLK, and 
GYSIFSYATK. A corresponding set of uniformly [13C]-
labeled leucine-containing peptides was also synthesized 
for three peptides, ESDTSYVS[13C6]LK, QDNEI[13C6]
LIFWSK, and AP[13C6]LTKP[13C6]LK, while in the case 
of the fourth peptide, a uniformly [13C]-labeled leucine 
was used in place of the naturally occurring isoleucine 
residue, GYS[13C6]LFSYATK (13C-CRP peptides). Peptide 
purity was assessed by reversed-phase chromatography 
and MALDI-TOF–MS. The sequences of the synthetic 
peptides were confirmed by MS/MS analysis of the pre-
cursor ions on a triple quadrupole mass spectrometer. 
MS/MS spectra for each peptide were generated on the 
doubly charged precursor ions and five sequence-specific 
transition ions were selected for subsequent MRM/MS 
analyses.
Pooled serum samples (1  mL) were diluted with two 
volumes of 200 mM ammonium bicarbonate buffer solu-
tion, and subjected to affinity depletion of abundant pro-
teins to remove HSA, IgG, and haptoglobin. This process 
is estimated to enrich the remaining serum components 
by effectively removing up to 90 % of the abundant pro-
teins, as assessed by SDS-PAGE, thus enabling up to a 
10-fold or greater enrichment of the proteins remaining 
in the mixture. [13C]-CRP peptides were spiked into the 
tryptic digest for use as internal standards in the quantifi-
cation of the corresponding endogenous peptides derived 
from the trypsinization of CRP [67]. Their study illus-
trates that the use of isotope-labeled synthetic peptides 
and MRM/MS is a powerful analytical method for the 
prescreening of candidate protein biomarkers in human 
serum such as CRP prior to antibody and immunoassay 
development [67].
HMGB1
Some 40-years ago, HMGB1 was identified as a non-
histone protein that is present in nucleus [6, 68, 69]. It 
is 30 kDa DNA-binding protein consisting of 215 amino 
acid residues that are organized into three domains, 
which include two tandem HMG box domains (A box 
and B box) that are arranged in an L-shaped configura-
tion, and a C-terminal tail of 30 amino acid residues 
(Fig.  7) [70, 71]. The nuclear localization of HMGB1 
is due to the presence of two lysine-rich nuclear locali-
zation sequences (NLSs) spanning amino acids 28–44 
(NLS1) and 179–185 (NLS2) [72]. HMGB1 is released 
from macrophages and monocytes by endogenous pro-
inflammatory cytokines such as tumor necrosis fac-
tor (TNF), interleukin [IL]-1β, interferon [IFN]-γ [68]. 
Because its N-terminus lacks a signal sequence, HMGB1 
cannot be released via the classical endoplasmic reticu-
lum–Golgi secretory pathway. Instead, activated mac-
rophages/monocytes acetylate the HMGB1-three of 
lysine residues in the NLS1 and five of the lysine residues 
in NLS2 (Fig.  7) [72], which leads to translocation into 
the cytoplasm and release into the extracellular milieu 
[73, 74].
HMGB1 is a pro-inflammatory cytokine that appears 
to be involved in atherosclerosis and other cardiovascu-
lar diseases [6]. For example, activated vascular smooth 
muscle cells were shown to be a source of HMGB1 in 
human advanced atherosclerotic lesions and it appeared 
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to directly stimulate the production of both CRP and 
matrix metalloproteinase through receptor for advanced 
glycation end product [75]. These findings suggest that 
HMGB1 produced by activated vascular smooth muscle 
cells could contribute to the progression of atherosclero-
sis by increasing the ability of atherosclerotic lesions to 
rupture [75]. In addition, experimental models of acute 
coronary syndromes and cerebrovascular accidents 
showed that HMGB1 is involved in the amplification 
of the inflammatory response that occurs during acute 
ischemic injury as well as in the recovery and remod-
eling that occurs after ischemia [69]. It is noteworthy 
that patients with acute coronary syndromes or stroke 
were found to have significantly higher serum levels of 
immunoreactive HMGB1 than healthy controls [76]. 
Furthermore, the increased HMGB1 levels were asso-
ciated with disease severity and mortality [69]. Finally, 
diet-induced atherosclerosis in ApoE-deficient mice 
could be prevented by HMGB1 expression using ethyl 
pyruvate [77]. In addition to its potential role in inflam-
mation and cardiovascular diseases, HMGB1 appears to 
be involved in drug-induced liver injury [78], alcoholic 
liver disease [79], pancreatic cancer [80], renal cancer 
[81], and mesothelioma [82]. However, in drug induced 
liver disease, alcoholic liver disease, and mesothelioma, 
the hyperacetylated form of HMGB1 is more important 
than the unmodified form. Interestingly, in alcoholic liver 
disease, serine-34 is also phosphorylated in the hypera-
cetylated HMGB1 (Fig. 7) [79].
The quantification of HMGB1 has generally been con-
ducted using immunoassay-based methodology such 
as ELISAs [83–87]. More recently, high specificity MS-
based methods that were developed by Antoine and his 
colleagues have been employed for HMGB1 analysis 
[79, 82, 88]. This has made it possible to distinguish the 
HMGB1 hyperacetylated forms from the unmodified 
form normally found in the nucleus (Fig. 7) [72]. The MS-
based methods are based upon the use of electrospray 
ionization (ESI)/MS analysis of intact HMGB1 protein 
followed by spectral deconvolution (Fig. 8) [82] or by the 
use of Glu-C protease digestion of the HMGB1 followed 
by ESI/tandem MS (MS/MS) analysis of the hyperacety-
lated NLS2-derived decapeptide K180SKKKKEEEE189, 
which contains five acetylated lysine residues [79].
Much of the MS-based methodology for analysis of 
HMGB1 and its acetylated isoforms has emerged from 
studies of drug induced-liver injury [88]. These methods 
have not yet been applied to studies of cardiovascular 
disease but they have already led to the discovery of a 
highly specific serum biomarker of mesothelioma [82]. 
LC–MS analysis of synthetic acetylated peptide from 
the NLS2 region of HMGB1 - K(Ac)SK(Ac)K(Ac)K(Ac)
K(Ac)EEEE, revealed that it could be rapidly adsorbed 
on plastic surfaces [88]. As a result, glass vials were 
required throughout the assay procedure. To minimize 
losses during LC–MS analysis a desalted tryptic digest 
of human serum albumin was used as a proteinaceous 
carrier for the synthetic peptide. They used a hybrid 
triple quadrupole-linear ion trap mass spectrometer 
and injected the synthetic peptide in a background of 
2.4  pmol/μL human serum albumin digest. HMGB1 
was isolated from 1  mL serum digested with Glu-C. 
The acetylated peptide was identical with the acetylated 
authentic standard peptide from NLS2 (Fig.  9). MRM/
MS transitions were based on the doubly charged par-
ent ion of m/z 736.8 (Fig.  9) and were selected as fol-
lows: 736.8/259 (y2–H2O), 736.8/341 (internal fragment 
ion K(Ac)K(Ac)), 736.8/428 (b3) and 736.8/598 (b4); 
the sodium adducted (doubly charged; m/z 747.8) and 
potassium adducted (doubly charged; m/z 755.3) pep-
tides were also included in the method. LC–MRM/MS 
analysis of serum revealed that acetylated HMGB1 was 
only elevated in patients that died or required a liver 
transplant or those that had a worse prognosis. Acety-
lated HMGB1 therefore holds potential as a prognostic 
indicator of drug induced liver injury.
Fig. 7 HMGB1 structure. A linear diagram of high-mobility group 
box 1 protein (HMGB1) is shown, including the residues that 
constitute the A-box (pink), B-box (purple) and acidic tail (green). The 
proximal A-box and B-box of HMGB1 both contain putative nuclear-
emigration signals, as identified by binding to the nuclear exportin 
chromosome-region maintenance 1. HMGB1 also contains 43 lysine 
residues, some of which are frequently acetylated in lipopolysaccha-
ride-activated macrophages (shown in bold). These lysine residues 
are found within two nuclear-localization signals (indicated by dashed 
boxes): NLS1, which spans amino acids 28–44; and NLS2, which spans 
amino acids 179–185. Reprinted with permission from [72]
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In a more recent study by Ge et al., HMGB1 was quan-
tified by LC–ESI/MS in serum and liver from a mouse 
model of alcoholic liver disease and from the serum of 
patients with alcoholic liver disease. Acetyl modifications 
were confirmed on lysine residues (K(Ac)) after LC–MS/
MS analysis, for peptides spanning NLS1 (amino acids 
27–39) (I) and NLS2 (amino acids 180–188 (179–187 
minus methionine) in HMGB1 derived from mice fed 
ethanol. In addition, a PTM was identified as serine-35 
phosphorylation by LC–MS/MS analysis of NLS1 in 
HMGB1 [79]. This modification was also observed in 
samples from subjects with alcohol-induced liver injury. 
Analysis of serum from mice and human subjects with 
alcoholic liver disease by LC–ESI/MS also revealed an 
increase in oxidation of HMGB1 to the disulfide isoform. 
Hepatocytes appeared to be a major source of these dif-
ferent HMGB1 isoforms. This suggests that hepatocyte 
HMGB1 participates in the pathogenesis of alcoholic 
liver disease and that HMGB1 undergoes PTMs that are 
involved in the mechanism of hepatotoxicity [79].
IGF‑I
IGF-I is a 70 amino acid 7.7 kDa protein, which acts as 
the principal mediator of the effects of growth hormone 
(GH) [89, 90]. It is largely synthesized in the liver (75 %) 
and, to a lesser extent, in peripheral tissues [91, 92]. GH 
directly regulates the production of IGF-1 and its prin-
ciple transport protein (IGF binding protein 3; IGF-BP3) 
[93]. Numerous studies have shown that lowered circu-
lating IGF-I levels are associated with an increased risk 
Fig. 8 Asbestos-exposed human mesothelin (HM) and malignant mesothelioma (MM) cells release different HMGB1 isoforms. a Representative 
spectrum of whole protein ESI/MS analysis of HMGB1 in crocidolite asbestos-exposed HM where only nonacetylated HMGB1 was detected. b Rep-
resentative spectrum of whole protein ESI/MS spectrum of HMGB1 in malignant mesothelioma cells where both hyperacetylated and nonacety-
lated HMGB1 were detected. Reprinted with permission from [82]
Fig. 9 Diagnostic LC–MS/MS spectrum of Glu-C-derived peptide confirming the identification of hyper-acetylated HMGB1 derived from inflam-
matory cells present in patient sera during acetaminophen hepatotoxicity. Amino acids, b and y ions and peptide sequences are indicated on each 
spectrum. Acetylated lysine residues within HMGB1 are represented by K(Ac). Reprinted with permission from [88]
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for cardiovascular disease [94–98]. Measuring serum GH 
levels have not proven to be a particularly useful diagnos-
tic tool because of the wide range of concentrations that 
were found [99]. By analyzing the peak GH response to a 
provocative test with insulin [100], GH secretory status 
can be assessed for the diagnosis of GH deficiency. Severe 
GH deficiency is defined by a peak GH response to insu-
lin of >3  µg/mL [101]. Insulin-induced hypoglycemia is 
unpleasant and contraindicated in patients with seizure 
disorders or ischemic heart disease [93]. In contrast, 
serum IGF-I circulates in a much narrower concentration 
range relative to GH, which means that it can be used as 
a biomarker for the clinical assessment of diseases related 
to GH deficiency or excess [102, 103].
IGF-I circulates primarily in a complex bound to its 
major carrier protein (IGFBP-3) and an acid labile subu-
nit. Consequently, it is necessary to disrupt this complex 
before analysis, an important factor in the development 
of assays for serum IGF-I [99]. However, it has been 
noted that IGF-I immunoassays are prone to interfer-
ences from IGFBPs [99] and that there is a lack of stand-
ardization and poor inter-assay agreement among the 
various IGF-I immunoassays [104–107]. A recent report 
showed that MS-based methodology can be employed in 
quantitation of serum IGF-I and promises to overcome 
many of the problems that have been encountered with 
these immunoassay procedures [99].
Ketha and Singh [99] have developed a LC–HRMS 
method for serum IGF-I quantitation. Serum was mixed 
with a buffer containing acidified ethanol to precipitate 
large proteins and to disrupt the IGF-I/IGFBP complex 
followed by centrifugation, neutralization, and a cooling 
step. IGF-I has a relatively small size and remains soluble 
in the supernatant. An SPE cleanup was employed before 
injection into LC–HRMA. Oxidized rat IGF-I (ratIGF-
IOx) was used as the internal standard. Quantification 
was performed using standards made from recombi-
nant IGF-I. The LC–HRMS method [108] method was 
extensively used in over 2000 samples and compared 
with the iSYS IGF-I automated immunoassay. A refer-
ence range was generated and the two methods were 
greatly correlated, with a reproducible systematic bias. 
The LC–HRMS method identified 16 outliers where the 
concentrations were lower than the ones from the iSYS 
immunoassay. Of the 16 samples examined, 15 had LC–
HRMS IGF-I concentrations of approximately 50  % of 
those obtained by the iSYS assay, whereas 1 sample had 
a MS result of <5  % of the immunoassay measurement. 
Reexamination of the HRMS data of these 16 samples led 
to the discovery of a protein variant with a mass m/z 1098 
that showed a spectrum with similar isotopic ratio as the 
monitored m/z 1093 charge envelope for IGF-I (most-
abundant observed m/z 1093.5214, [M + 7H]7+). When 
the protein variant peak was quantitated and summed 
with the IGF-I results, the LC–HRMS IGF-I values 
closely matched those of the iSYS immunoassay, leading 
to the conclusion that the protein variant was related to 
IGF-I. Additional LC–HRMS IGF-I analysis revealed that 
this variant was present in approximately 0.6  % of the 
patient population.
Using the LC–HRMS method, a common variant 
A70T-IGF1, was identified. The variant could not be 
distinguished from wild-type by the available immu-
noassays. When known pathogenic mutations exist or 
discordant results with established immunoassays are 
discovered, variant protein sequences should be consid-
ered and evaluated. Furthermore, when LC–MS assays 
give unexpectedly low results, the possibility of the pres-
ence of variants should be considered. Consequently, the 
LC–HRMS method can provide opportunities for more 
definitive genetic family testing that would be missed by 
immunoassay procedures [99].
Summary and future directions
Protein quantification using SILAC labeled proteins has 
become the method of choice for proteomics studies 
[109–111]. However, rigorous method validation using 
full-length correctly folded stable isotope labeled protein 
internal standards is still under-utilized [13]. We recently 
developed an assay for serum ApoA-I using LC–MRM/
MS together with nine tryptic peptides generated from 
native ApoA-I and SILAC-labeled ApoA-I [4]. This meth-
odology can now be employed to explore subtle changes 
in ApoA-I levels as a potential biomarker of cardiovas-
cular disease and as a biological response indicator for 
tobacco smoking to complement the use of urinary nico-
tine metabolites [112], NNAL [113], isoprostanes [114], 
and 8-oxo-dGuo [115]. It will also serve as a gold stand-
ard to validate other LC–MS and immunoassay-based 
procedures for serum ApoA-I. It is also noteworthy that 
the AQUA internal standards (rather than an intact 
labeled protein) did not provide adequate accuracy and 
specificity for the analysis of serum ApoA-I [29, 30].
There are an increasing number of examples where 
MS-based protein quantification provides important 
data [3–5, 64, 79, 82, 99, 108] that cannot be obtained 
with than less labor intensive and cheaper immunoas-
say-based procedures. It is anticipated that this will lead 
to significant advances in a number of important issues 
related to the role of specific proteins in cardiovascu-
lar diseases [14, 17, 43, 51, 69, 116]. The availability of a 
new generation of high resolution high sensitivity mass 
spectrometers will greatly facilitate these studies as it 
will be possible to analyze important proteins with lev-
els of specificity and sensitivity that cannot be attained by 
immunoassay-based procedures. The gain in specificity 
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and sensitivity will more than compensate for the extra 
complexity and cost. At the very least, MS-based protein 
quantification methods can provide “gold standards” to 
confirm that immunoassay-based procedures are accu-
rately quantifying the correct analyte (Table 1).
The stable isotope dilution LC–MRM/MS assays for 
serum proteins are complex and can only be performed 
in a limited number of laboratories. However, the assay 
will have clinical utility for providing definitive informa-
tion on the effects of therapeutic interventions in high-
risk populations. Such individualization of therapy is 
currently not possible in most clinical laboratories, but 
with the actual advances of the new instruments it is 
likely that this technique will start to be used in clinical 
settings.
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